Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluatie van de toevoeging van het immunotherapie-medicijn atezolizumab aan standaard chemotherapiebehandeling voor gevorderde of gemetastaseerde neuro-endocriene carcinomen die buiten de long ontstaan

17 november 2026 bijgewerkt door: National Cancer Institute (NCI)

Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.

Studie Overzicht

Gedetailleerde beschrijving

PRIMARY OBJECTIVES:

I. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3).

II. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3).

III. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2).

SECONDARY OBJECTIVES:

I. To compare overall survival (OS), measured from start of observation/maintenance, across arms.

II. To compare progression free survival (PFS) (measured from randomization and measured from start of observation/maintenance) across arms.

III. To compare objective response rate (ORR = confirmed and unconfirmed partial response [PR] + confirmed and unconfirmed complete response [CR]) across arms among patients with measurable disease at randomization.

IV. To compare clinical benefit rate (CBR = confirmed and unconfirmed PR + confirmed and unconfirmed CR + stable disease [SD]) across arms among patients with measurable disease at randomization.

V. To compare duration of response (DOR) across arms. VI. To evaluate the safety and tolerability of each arm.

ADDITIONAL OBJECTIVE:

I. To bank tumor and blood samples for future biomarker correlative studies.

OUTLINE: Patients are randomized to 1 of 3 arms.

ARM I: During induction phase, patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.

ARM II (CLOSED TO ACCRUAL 7/9/26): During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.

ARM III: During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.

Patients in all arms also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial and blood sample collection on study.

After completion of study treatment, patients are followed up for 5 years.

Studietype

Ingrijpend

Inschrijving (Geschat)

189

Fase

  • Fase 2
  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Alaska
      • Anchorage, Alaska, Verenigde Staten, 99508
        • Geschorst
        • Alaska Women's Cancer Care
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85004
      • Phoenix, Arizona, Verenigde Staten, 85054
        • Werving
        • Mayo Clinic Hospital in Arizona
        • Hoofdonderzoeker:
          • Jacob Orme
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 855-776-0015
    • California
      • Anaheim, California, Verenigde Staten, 92806
        • Werving
        • Kaiser Permanente-Anaheim
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Auburn, California, Verenigde Staten, 95602
      • Auburn, California, Verenigde Staten, 95603
        • Werving
        • Sutter Cancer Centers Radiation Oncology Services-Auburn
        • Hoofdonderzoeker:
          • Kristie A. Bobolis
        • Contact:
      • Baldwin Park, California, Verenigde Staten, 91706
        • Werving
        • Kaiser Permanente-Baldwin Park
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Bellflower, California, Verenigde Staten, 90706
        • Werving
        • Kaiser Permanente-Bellflower
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Berkeley, California, Verenigde Staten, 94704
        • Werving
        • Alta Bates Summit Medical Center-Herrick Campus
        • Hoofdonderzoeker:
          • Kristie A. Bobolis
        • Contact:
      • Cameron Park, California, Verenigde Staten, 95682
        • Werving
        • Sutter Cancer Centers Radiation Oncology Services-Cameron Park
        • Hoofdonderzoeker:
          • Kristie A. Bobolis
        • Contact:
      • Carmichael, California, Verenigde Staten, 95608
      • Carmichael, California, Verenigde Staten, 95608
      • Elk Grove, California, Verenigde Staten, 95758
      • Fontana, California, Verenigde Staten, 92335
        • Werving
        • Kaiser Permanente-Fontana
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Fremont, California, Verenigde Staten, 94538
      • Harbor City, California, Verenigde Staten, 90710
        • Werving
        • Kaiser Permanente South Bay
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Irvine, California, Verenigde Staten, 92618
        • Werving
        • Kaiser Permanente-Irvine
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Los Angeles, California, Verenigde Staten, 90027
        • Werving
        • Kaiser Permanente Los Angeles Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Los Angeles, California, Verenigde Staten, 90034
        • Werving
        • Kaiser Permanente West Los Angeles
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Modesto, California, Verenigde Staten, 95355
      • Mountain View, California, Verenigde Staten, 94040
      • Ontario, California, Verenigde Staten, 91761
        • Werving
        • Kaiser Permanente-Ontario
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Palo Alto, California, Verenigde Staten, 94301
      • Panorama City, California, Verenigde Staten, 91402
        • Werving
        • Kaiser Permanente - Panorama City
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Riverside, California, Verenigde Staten, 92505
        • Werving
        • Kaiser Permanente-Riverside
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Rocklin, California, Verenigde Staten, 95765
      • Roseville, California, Verenigde Staten, 95661
        • Werving
        • Sutter Cancer Centers Radiation Oncology Services-Roseville
        • Hoofdonderzoeker:
          • Kristie A. Bobolis
        • Contact:
      • Roseville, California, Verenigde Staten, 95661
      • Sacramento, California, Verenigde Staten, 95816
      • Sacramento, California, Verenigde Staten, 95816
      • San Diego, California, Verenigde Staten, 92120
        • Werving
        • Kaiser Permanente-San Diego Zion
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • San Francisco, California, Verenigde Staten, 94115
        • Werving
        • California Pacific Medical Center-Pacific Campus
        • Hoofdonderzoeker:
          • Kristie A. Bobolis
        • Contact:
      • San Marcos, California, Verenigde Staten, 92078
        • Werving
        • Kaiser Permanente-San Marcos
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
      • Santa Cruz, California, Verenigde Staten, 95065
      • Santa Rosa, California, Verenigde Staten, 95403
        • Werving
        • Sutter Pacific Medical Foundation
        • Hoofdonderzoeker:
          • Kristie A. Bobolis
        • Contact:
      • Sunnyvale, California, Verenigde Staten, 94086
      • Vallejo, California, Verenigde Staten, 94589
      • Woodland, California, Verenigde Staten, 95695
      • Woodland Hills, California, Verenigde Staten, 91367
        • Werving
        • Kaiser Permanente-Woodland Hills
        • Contact:
        • Hoofdonderzoeker:
          • Helen H. Moon
    • Colorado
      • Denver, Colorado, Verenigde Staten, 80210
      • Littleton, Colorado, Verenigde Staten, 80122
      • Parker, Colorado, Verenigde Staten, 80138
    • Connecticut
      • Derby, Connecticut, Verenigde Staten, 06418
        • Werving
        • Smilow Cancer Hospital-Derby Care Center
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Fairfield, Connecticut, Verenigde Staten, 06824
        • Werving
        • Smilow Cancer Hospital Care Center-Fairfield
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Glastonbury, Connecticut, Verenigde Staten, 06033
        • Geschorst
        • Smilow Cancer Hospital Care Center at Glastonbury
      • Greenwich, Connecticut, Verenigde Staten, 06830
        • Werving
        • Smilow Cancer Hospital Care Center at Greenwich
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Guilford, Connecticut, Verenigde Staten, 06437
        • Werving
        • Smilow Cancer Hospital Care Center - Guilford
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Hartford, Connecticut, Verenigde Staten, 06105
        • Geschorst
        • Smilow Cancer Hospital Care Center at Saint Francis
      • New Haven, Connecticut, Verenigde Staten, 06520
        • Werving
        • Yale University
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • North Haven, Connecticut, Verenigde Staten, 06473
        • Werving
        • Yale-New Haven Hospital North Haven Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Stamford, Connecticut, Verenigde Staten, 06902
        • Werving
        • Smilow Cancer Hospital Care Center at Long Ridge
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Torrington, Connecticut, Verenigde Staten, 06790
        • Werving
        • Smilow Cancer Hospital-Torrington Care Center
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Trumbull, Connecticut, Verenigde Staten, 06611
        • Werving
        • Smilow Cancer Hospital Care Center-Trumbull
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Waterbury, Connecticut, Verenigde Staten, 06708
        • Werving
        • Smilow Cancer Hospital-Waterbury Care Center
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
      • Waterford, Connecticut, Verenigde Staten, 06385
        • Werving
        • Smilow Cancer Hospital Care Center - Waterford
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
    • Florida
      • Fort Lauderdale, Florida, Verenigde Staten, 33308
      • Jacksonville, Florida, Verenigde Staten, 32224-9980
        • Werving
        • Mayo Clinic in Florida
        • Hoofdonderzoeker:
          • Jacob Orme
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 855-776-0015
      • Tampa, Florida, Verenigde Staten, 33612
        • Werving
        • Moffitt Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Mintallah Haider
    • Hawaii
      • Honolulu, Hawaii, Verenigde Staten, 96813
        • Werving
        • Hawaii Cancer Care Inc - Waterfront Plaza
        • Contact:
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Verenigde Staten, 96813
        • Werving
        • Queen's Cancer Cenrer - POB I
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 808-532-0315
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Verenigde Staten, 96813
        • Werving
        • Queen's Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 808-545-8548
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Verenigde Staten, 96813
        • Werving
        • Straub Clinic and Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 808-522-4333
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Verenigde Staten, 96813
        • Werving
        • University of Hawaii Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 808-586-2979
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • Honolulu, Hawaii, Verenigde Staten, 96817
        • Werving
        • Queen's Cancer Center - Kuakini
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 808-531-8521
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • ‘Aiea, Hawaii, Verenigde Staten, 96701
        • Werving
        • Hawaii Cancer Care - Westridge
        • Contact:
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
      • ‘Aiea, Hawaii, Verenigde Staten, 96701
        • Geschorst
        • Pali Momi Medical Center
      • ‘Ewa Beach, Hawaii, Verenigde Staten, 96706
        • Werving
        • The Queen's Medical Center - West Oahu
        • Contact:
        • Hoofdonderzoeker:
          • Elizabeth S. Nakasone
    • Idaho
      • Coeur d'Alene, Idaho, Verenigde Staten, 83814
        • Werving
        • Kootenai Health - Coeur d'Alene
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
      • Nampa, Idaho, Verenigde Staten, 83687
        • Werving
        • Saint Alphonsus Cancer Care Center-Nampa
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Post Falls, Idaho, Verenigde Staten, 83854
        • Werving
        • Kootenai Clinic Cancer Services - Post Falls
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
      • Sandpoint, Idaho, Verenigde Staten, 83864
        • Werving
        • Kootenai Clinic Cancer Services - Sandpoint
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
    • Illinois
      • Aurora, Illinois, Verenigde Staten, 60504
        • Geschorst
        • Rush-Copley Medical Center
      • Centralia, Illinois, Verenigde Staten, 62801
        • Werving
        • Centralia Oncology Clinic
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
      • Chicago, Illinois, Verenigde Staten, 60637
        • Werving
        • University of Chicago Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Ardaman Shergill
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Northwestern University
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
      • Danville, Illinois, Verenigde Staten, 61832
        • Werving
        • Carle at The Riverfront
        • Hoofdonderzoeker:
          • Vamsi K. Vasireddy
        • Contact:
      • DeKalb, Illinois, Verenigde Staten, 60115
        • Werving
        • Northwestern Medicine Cancer Center Kishwaukee
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
      • Decatur, Illinois, Verenigde Staten, 62526
        • Werving
        • Cancer Care Specialists of Illinois - Decatur
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
      • Decatur, Illinois, Verenigde Staten, 62526
        • Werving
        • Decatur Memorial Hospital
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
      • Effingham, Illinois, Verenigde Staten, 62401
        • Werving
        • Carle Physician Group-Effingham
        • Contact:
        • Hoofdonderzoeker:
          • Vamsi K. Vasireddy
      • Effingham, Illinois, Verenigde Staten, 62401
        • Werving
        • Crossroads Cancer Center
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
      • Geneva, Illinois, Verenigde Staten, 60134
        • Werving
        • Northwestern Medicine Cancer Center Delnor
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
      • Glenview, Illinois, Verenigde Staten, 60026
        • Werving
        • Northwestern Medicine Glenview Outpatient Center
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 312-695-1102
      • Grayslake, Illinois, Verenigde Staten, 60030
        • Werving
        • Northwestern Medicine Grayslake Outpatient Center
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 312-695-1102
      • Harvey, Illinois, Verenigde Staten, 60426
        • Werving
        • Ingalls Memorial Hospital
        • Hoofdonderzoeker:
          • James A. Wallace
        • Contact:
      • Lake Forest, Illinois, Verenigde Staten, 60045
        • Werving
        • Northwestern Medicine Lake Forest Hospital
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
      • Mattoon, Illinois, Verenigde Staten, 61938
        • Werving
        • Carle Physician Group-Mattoon/Charleston
        • Contact:
        • Hoofdonderzoeker:
          • Vamsi K. Vasireddy
      • Mount Vernon, Illinois, Verenigde Staten, 62864
        • Werving
        • SSM Health Good Samaritan
        • Hoofdonderzoeker:
          • Jay W. Carlson
        • Contact:
      • New Lenox, Illinois, Verenigde Staten, 60451
        • Werving
        • UC Comprehensive Cancer Center at Silver Cross
        • Contact:
        • Hoofdonderzoeker:
          • Ardaman Shergill
      • Normal, Illinois, Verenigde Staten, 61761
        • Werving
        • Carle BroMenn Medical Center
        • Hoofdonderzoeker:
          • Vamsi K. Vasireddy
        • Contact:
      • Normal, Illinois, Verenigde Staten, 61761
        • Werving
        • Carle Cancer Institute Normal
        • Hoofdonderzoeker:
          • Vamsi K. Vasireddy
        • Contact:
      • O'Fallon, Illinois, Verenigde Staten, 62269
        • Werving
        • Cancer Care Center of O'Fallon
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
      • Orland Park, Illinois, Verenigde Staten, 60462
        • Werving
        • University of Chicago Medicine-Orland Park
        • Contact:
        • Hoofdonderzoeker:
          • Ardaman Shergill
      • Orland Park, Illinois, Verenigde Staten, 60462
      • Rockford, Illinois, Verenigde Staten, 61114
        • Werving
        • UW Health Carbone Cancer Center Rockford
        • Contact:
        • Hoofdonderzoeker:
          • Fahrettin Covut
      • Springfield, Illinois, Verenigde Staten, 62702
        • Werving
        • Southern Illinois University School of Medicine
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 217-545-7929
      • Springfield, Illinois, Verenigde Staten, 62702
        • Werving
        • Springfield Clinic
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-444-7541
      • Springfield, Illinois, Verenigde Staten, 62781
        • Werving
        • Springfield Memorial Hospital
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
      • Urbana, Illinois, Verenigde Staten, 61801
        • Werving
        • Carle Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Vamsi K. Vasireddy
      • Warrenville, Illinois, Verenigde Staten, 60555
        • Werving
        • Northwestern Medicine Cancer Center Warrenville
        • Hoofdonderzoeker:
          • Mary F. Mulcahy
        • Contact:
      • Yorkville, Illinois, Verenigde Staten, 60560
        • Geschorst
        • Rush-Copley Healthcare Center
    • Indiana
      • Crown Point, Indiana, Verenigde Staten, 46307
    • Iowa
      • Ames, Iowa, Verenigde Staten, 50010
        • Werving
        • Mary Greeley Medical Center
        • Hoofdonderzoeker:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-956-4132
      • Ames, Iowa, Verenigde Staten, 50010
        • Werving
        • McFarland Clinic - Ames
        • Hoofdonderzoeker:
          • Joseph J. Merchant
        • Contact:
      • Ankeny, Iowa, Verenigde Staten, 50023
        • Werving
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Boone, Iowa, Verenigde Staten, 50036
        • Geschorst
        • McFarland Clinic - Boone
      • Carroll, Iowa, Verenigde Staten, 51401
        • Werving
        • Saint Anthony Regional Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Clive, Iowa, Verenigde Staten, 50325
        • Werving
        • Mercy Cancer Center-West Lakes
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Richard L. Deming
      • Clive, Iowa, Verenigde Staten, 50325
        • Werving
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Creston, Iowa, Verenigde Staten, 50801
        • Actief, niet wervend
        • Greater Regional Medical Center
      • Des Moines, Iowa, Verenigde Staten, 50314
        • Werving
        • Broadlawns Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-282-2200
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Verenigde Staten, 50314
        • Werving
        • Mercy Medical Center - Des Moines
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Richard L. Deming
      • Des Moines, Iowa, Verenigde Staten, 50309
        • Werving
        • Iowa Methodist Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-6727
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Verenigde Staten, 50309
        • Werving
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Des Moines, Iowa, Verenigde Staten, 50314
        • Werving
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • Fort Dodge, Iowa, Verenigde Staten, 50501
        • Werving
        • McFarland Clinic - Trinity Cancer Center
        • Hoofdonderzoeker:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-956-4132
      • Jefferson, Iowa, Verenigde Staten, 50129
        • Geschorst
        • McFarland Clinic - Jefferson
      • Marshalltown, Iowa, Verenigde Staten, 50158
        • Werving
        • McFarland Clinic - Marshalltown
        • Hoofdonderzoeker:
          • Joseph J. Merchant
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-956-4132
      • Waukee, Iowa, Verenigde Staten, 50263
        • Werving
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Seema Harichand-Herdt
      • West Des Moines, Iowa, Verenigde Staten, 50266
        • Werving
        • Mercy Medical Center-West Lakes
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 515-241-3305
        • Hoofdonderzoeker:
          • Richard L. Deming
    • Louisiana
      • Baton Rouge, Louisiana, Verenigde Staten, 70805
        • Werving
        • LSU Health Baton Rouge-North Clinic
        • Contact:
        • Hoofdonderzoeker:
          • Marshall P. Stagg
      • Baton Rouge, Louisiana, Verenigde Staten, 70808
        • Werving
        • Our Lady of the Lake Physician Group
        • Contact:
        • Hoofdonderzoeker:
          • Marshall P. Stagg
      • Metairie, Louisiana, Verenigde Staten, 70006
        • Werving
        • East Jefferson General Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Tara Castellano
      • Metairie, Louisiana, Verenigde Staten, 70006
        • Werving
        • LSU Healthcare Network / Metairie Multi-Specialty Clinic
        • Contact:
        • Hoofdonderzoeker:
          • Tara Castellano
      • New Orleans, Louisiana, Verenigde Staten, 70112
        • Werving
        • University Medical Center New Orleans
        • Contact:
        • Hoofdonderzoeker:
          • Tara Castellano
    • Massachusetts
      • Burlington, Massachusetts, Verenigde Staten, 01805
      • Peabody, Massachusetts, Verenigde Staten, 01960
    • Michigan
      • Ann Arbor, Michigan, Verenigde Staten, 48109
        • Werving
        • University of Michigan Rogel Cancer Center
        • Hoofdonderzoeker:
          • Vaibhav Sahai
        • Contact:
      • Ann Arbor, Michigan, Verenigde Staten, 48106
        • Werving
        • Trinity Health Saint Joseph Mercy Hospital Ann Arbor
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Battle Creek, Michigan, Verenigde Staten, 49017
        • Werving
        • Bronson Battle Creek
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Brighton, Michigan, Verenigde Staten, 48114
        • Werving
        • Trinity Health IHA Medical Group Hematology Oncology - Brighton
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Brighton, Michigan, Verenigde Staten, 48114
      • Brownstown, Michigan, Verenigde Staten, 48183
        • Werving
        • Henry Ford Cancer Institute-Downriver
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Canton, Michigan, Verenigde Staten, 48188
        • Werving
        • Trinity Health IHA Medical Group Hematology Oncology - Canton
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Canton, Michigan, Verenigde Staten, 48188
      • Chelsea, Michigan, Verenigde Staten, 48118
        • Werving
        • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Chelsea, Michigan, Verenigde Staten, 48118
      • Clinton Township, Michigan, Verenigde Staten, 48038
        • Werving
        • Henry Ford Macomb Hospital-Clinton Township
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Dearborn, Michigan, Verenigde Staten, 48126
        • Werving
        • Henry Ford Medical Center-Fairlane
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Dearborn, Michigan, Verenigde Staten, 48124
        • Werving
        • Corewell Health Dearborn Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 248-551-7695
        • Hoofdonderzoeker:
          • Andrew A. Muskovitz
      • Detroit, Michigan, Verenigde Staten, 48202
        • Werving
        • Henry Ford Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Detroit, Michigan, Verenigde Staten, 48201
        • Actief, niet wervend
        • Wayne State University/Karmanos Cancer Institute
      • Detroit, Michigan, Verenigde Staten, 48236
        • Werving
        • Henry Ford Health Saint John Hospital
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • East China Township, Michigan, Verenigde Staten, 48054
        • Werving
        • Henry Ford River District Hospital
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Farmington Hills, Michigan, Verenigde Staten, 48334
        • Actief, niet wervend
        • Weisberg Cancer Treatment Center
      • Farmington Hills, Michigan, Verenigde Staten, 48336
        • Werving
        • Corewell Health Farmington Hills Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 248-551-7695
        • Hoofdonderzoeker:
          • Andrew A. Muskovitz
      • Flint, Michigan, Verenigde Staten, 48503
        • Werving
        • Genesys Hurley Cancer Institute
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Flint, Michigan, Verenigde Staten, 48503
        • Werving
        • Hurley Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Flint, Michigan, Verenigde Staten, 48503
        • Geschorst
        • Genesee Hematology Oncology PC
      • Flint, Michigan, Verenigde Staten, 48503
        • Werving
        • Cancer Hematology Centers - Flint
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • Trinity Health Grand Rapids Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Grand Rapids, Michigan, Verenigde Staten, 49503
        • Werving
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
        • Werving
        • Henry Ford Saint John Hospital - Breast
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
        • Werving
        • Henry Ford Saint John Hospital - Academic
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Grosse Pointe Woods, Michigan, Verenigde Staten, 48236
        • Werving
        • Henry Ford Saint John Hospital - Van Elslander
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Jackson, Michigan, Verenigde Staten, 49201
        • Werving
        • Allegiance Health
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • Werving
        • Bronson Methodist Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • Werving
        • West Michigan Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Lansing, Michigan, Verenigde Staten, 48910
        • Actief, niet wervend
        • Karmanos Cancer Institute at McLaren Greater Lansing
      • Livonia, Michigan, Verenigde Staten, 48154
        • Werving
        • Trinity Health Saint Mary Mercy Livonia Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Macomb, Michigan, Verenigde Staten, 48044
        • Werving
        • Henry Ford Warren Hospital - Breast Macomb
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Macomb, Michigan, Verenigde Staten, 48044
        • Werving
        • Henry Ford Saint John Hospital - Macomb Medical
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Muskegon, Michigan, Verenigde Staten, 49444
        • Werving
        • Trinity Health Muskegon Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Niles, Michigan, Verenigde Staten, 49120
        • Werving
        • Corewell Health Lakeland Hospitals - Niles Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 616-391-1230
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Norton Shores, Michigan, Verenigde Staten, 49444
        • Geschorst
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Novi, Michigan, Verenigde Staten, 48377
        • Werving
        • Henry Ford Medical Center-Columbus
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Pontiac, Michigan, Verenigde Staten, 48341
        • Werving
        • Trinity Health Saint Joseph Mercy Oakland Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
      • Reed City, Michigan, Verenigde Staten, 49677
        • Werving
        • Corewell Health Reed City Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Royal Oak, Michigan, Verenigde Staten, 48073
        • Werving
        • Corewell Health William Beaumont University Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 248-551-7695
        • Hoofdonderzoeker:
          • Andrew A. Muskovitz
      • Saint Joseph, Michigan, Verenigde Staten, 49085
        • Werving
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Verenigde Staten, 49085
        • Werving
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Traverse City, Michigan, Verenigde Staten, 49684
        • Werving
        • Munson Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Troy, Michigan, Verenigde Staten, 48085
        • Werving
        • Corewell Health Beaumont Troy Hospital
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 248-551-7695
        • Hoofdonderzoeker:
          • Andrew A. Muskovitz
      • Warren, Michigan, Verenigde Staten, 48093
        • Werving
        • Henry Ford Madison Heights Hospital - Breast
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Warren, Michigan, Verenigde Staten, 48093
        • Werving
        • Henry Ford Health Warren Hospital
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • Warren, Michigan, Verenigde Staten, 48093
        • Werving
        • Henry Ford Warren Hospital - GLCMS
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
        • Contact:
      • West Bloomfield, Michigan, Verenigde Staten, 48322
        • Werving
        • Henry Ford West Bloomfield Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Haythem Y. Ali
      • Wyandotte, Michigan, Verenigde Staten, 48192
        • Werving
        • Henry Ford Wyandotte Hospital
        • Hoofdonderzoeker:
          • Haythem Y. Ali
        • Contact:
      • Wyoming, Michigan, Verenigde Staten, 49519
        • Werving
        • University of Michigan Health - West
        • Contact:
        • Hoofdonderzoeker:
          • Kathleen Y. Butler
      • Ypsilanti, Michigan, Verenigde Staten, 48106
      • Ypsilanti, Michigan, Verenigde Staten, 48197
        • Werving
        • Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
        • Contact:
        • Hoofdonderzoeker:
          • Tareq Al baghdadi
    • Minnesota
      • Burnsville, Minnesota, Verenigde Staten, 55337
        • Werving
        • Minnesota Oncology - Burnsville
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Duluth, Minnesota, Verenigde Staten, 55805
        • Actief, niet wervend
        • Saint Luke's Hospital of Duluth
      • Edina, Minnesota, Verenigde Staten, 55435
        • Werving
        • Fairview Southdale Hospital
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Edina, Minnesota, Verenigde Staten, 55435
        • Werving
        • Minnesota Oncology - Edina
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Werving
        • Abbott-Northwestern Hospital
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Minneapolis, Minnesota, Verenigde Staten, 55415
        • Werving
        • Hennepin County Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Werving
        • Mayo Clinic in Rochester
        • Hoofdonderzoeker:
          • Jacob Orme
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 855-776-0015
      • Saint Louis Park, Minnesota, Verenigde Staten, 55416
        • Werving
        • Park Nicollet Clinic - Saint Louis Park
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Saint Paul, Minnesota, Verenigde Staten, 55101
        • Werving
        • Regions Hospital
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Saint Paul, Minnesota, Verenigde Staten, 55102
        • Werving
        • United Hospital
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
      • Shakopee, Minnesota, Verenigde Staten, 55379
        • Werving
        • Saint Francis Regional Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • David M. King
    • Missouri
      • Cape Girardeau, Missouri, Verenigde Staten, 63703
        • Werving
        • Saint Francis Medical Center
        • Hoofdonderzoeker:
          • Bryan A. Faller
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 573-334-2230
          • E-mail: sfmc@sfmc.net
      • Joplin, Missouri, Verenigde Staten, 64804
        • Werving
        • Mercy Hospital Joplin
        • Hoofdonderzoeker:
          • Jay W. Carlson
        • Contact:
      • Springfield, Missouri, Verenigde Staten, 65804
        • Werving
        • Mercy Hospital Springfield
        • Hoofdonderzoeker:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 417-269-4520
      • Springfield, Missouri, Verenigde Staten, 65807
        • Werving
        • CoxHealth South Hospital
        • Hoofdonderzoeker:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 417-269-4520
      • St Louis, Missouri, Verenigde Staten, 63128
        • Werving
        • Mercy Hospital South
        • Hoofdonderzoeker:
          • Jay W. Carlson
        • Contact:
    • Montana
      • Anaconda, Montana, Verenigde Staten, 59711
        • Werving
        • Community Hospital of Anaconda
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
      • Billings, Montana, Verenigde Staten, 59101
        • Werving
        • Billings Clinic Cancer Center
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
      • Billings, Montana, Verenigde Staten, 59102
        • Werving
        • Saint Vincent Frontier Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-648-6274
        • Hoofdonderzoeker:
          • Patrick W. Cobb
      • Great Falls, Montana, Verenigde Staten, 59405
        • Werving
        • Benefis Sletten Cancer Institute
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
      • Kalispell, Montana, Verenigde Staten, 59901
        • Werving
        • Logan Health Medical Center
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
      • Missoula, Montana, Verenigde Staten, 59804
        • Werving
        • Community Medical Center
        • Hoofdonderzoeker:
          • John M. Schallenkamp
        • Contact:
    • New Hampshire
      • Lebanon, New Hampshire, Verenigde Staten, 03756
        • Werving
        • Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Kathryn C. Hourdequin
    • New York
      • Buffalo, New York, Verenigde Staten, 14263
        • Actief, niet wervend
        • Roswell Park Cancer Institute
      • New York, New York, Verenigde Staten, 10029
        • Actief, niet wervend
        • Mount Sinai Hospital
      • Stony Brook, New York, Verenigde Staten, 11794
        • Actief, niet wervend
        • Stony Brook University Medical Center
    • North Carolina
      • Cary, North Carolina, Verenigde Staten, 27518
        • Geschorst
        • Duke Cancer Center Cary
      • Charlotte, North Carolina, Verenigde Staten, 28203
        • Werving
        • Carolinas Medical Center/Levine Cancer Institute
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
      • Charlotte, North Carolina, Verenigde Staten, 28210
        • Werving
        • Atrium Health Pineville/LCI-Pineville
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 980-442-2000
      • Charlotte, North Carolina, Verenigde Staten, 28211
        • Werving
        • Levine Cancer Institute-SouthPark
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 980-442-2000
      • Charlotte, North Carolina, Verenigde Staten, 28262
        • Werving
        • Atrium Health University City/LCI-University
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
      • Charlotte, North Carolina, Verenigde Staten, 28277
        • Werving
        • Levine Cancer Institute-Ballantyne
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
      • Clinton, North Carolina, Verenigde Staten, 28328
        • Werving
        • Southeastern Medical Oncology Center-Clinton
        • Contact:
        • Hoofdonderzoeker:
          • Samer S. Kasbari
      • Concord, North Carolina, Verenigde Staten, 28025
        • Werving
        • Atrium Health Cabarrus/LCI-Concord
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
      • Durham, North Carolina, Verenigde Staten, 27710
        • Werving
        • Duke University Medical Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 888-275-3853
        • Hoofdonderzoeker:
          • Tucker Coston
      • Gastonia, North Carolina, Verenigde Staten, 28054
        • Werving
        • Levine Cancer Institute-Gaston
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
      • Goldsboro, North Carolina, Verenigde Staten, 27534
        • Werving
        • Southeastern Medical Oncology Center-Goldsboro
        • Contact:
        • Hoofdonderzoeker:
          • Samer S. Kasbari
      • Jacksonville, North Carolina, Verenigde Staten, 28546
        • Werving
        • Southeastern Medical Oncology Center-Jacksonville
        • Hoofdonderzoeker:
          • Samer S. Kasbari
        • Contact:
      • Pinehurst, North Carolina, Verenigde Staten, 28374
        • Werving
        • FirstHealth of the Carolinas-Moore Regional Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Charles S. Kuzma
      • Raleigh, North Carolina, Verenigde Staten, 27609
        • Werving
        • Duke Cancer Center Raleigh
        • Contact:
        • Hoofdonderzoeker:
          • Tucker Coston
      • Shelby, North Carolina, Verenigde Staten, 28150
        • Werving
        • Atrium Health Cleveland/LCI-Cleveland
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43210
        • Werving
        • Ohio State University Comprehensive Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Bhavana Konda
      • Toledo, Ohio, Verenigde Staten, 43623
        • Geschorst
        • Toledo Clinic Cancer Centers-Toledo
    • Oklahoma
      • Lawton, Oklahoma, Verenigde Staten, 73505
        • Werving
        • Cancer Centers of Southwest Oklahoma Research
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-231-4440
        • Hoofdonderzoeker:
          • Sagila George
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Werving
        • University of Oklahoma Health Sciences Center
        • Contact:
        • Hoofdonderzoeker:
          • Sagila George
      • Oklahoma City, Oklahoma, Verenigde Staten, 73120
        • Werving
        • Mercy Hospital Oklahoma City
        • Hoofdonderzoeker:
          • Jay W. Carlson
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 405-752-3402
    • Oregon
      • Bend, Oregon, Verenigde Staten, 97701
        • Werving
        • Saint Charles Health System
        • Contact:
        • Hoofdonderzoeker:
          • Charles W. Drescher
      • Clackamas, Oregon, Verenigde Staten, 97015
        • Geschorst
        • Providence Cancer Institute Clackamas Clinic
      • Newberg, Oregon, Verenigde Staten, 97132
        • Werving
        • Providence Newberg Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Charles W. Drescher
      • Oregon City, Oregon, Verenigde Staten, 97045
        • Werving
        • Providence Willamette Falls Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Charles W. Drescher
      • Portland, Oregon, Verenigde Staten, 97213
        • Werving
        • Providence Portland Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Charles W. Drescher
      • Portland, Oregon, Verenigde Staten, 97225
        • Werving
        • Providence Saint Vincent Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Charles W. Drescher
    • Pennsylvania
      • Chambersburg, Pennsylvania, Verenigde Staten, 17201
        • Werving
        • WellSpan Medical Oncology and Hematology
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 717-217-6020
        • Hoofdonderzoeker:
          • Marianne Spengler
      • Ephrata, Pennsylvania, Verenigde Staten, 17522
        • Werving
        • Ephrata Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 717-721-4840
        • Hoofdonderzoeker:
          • Marianne Spengler
      • Gettysburg, Pennsylvania, Verenigde Staten, 17325
        • Werving
        • Adams Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-441-7957
        • Hoofdonderzoeker:
          • Marianne Spengler
      • Hanover, Pennsylvania, Verenigde Staten, 17331
        • Werving
        • WellSpan Medical Oncology and Hematology
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 717-632-1559
        • Hoofdonderzoeker:
          • Marianne Spengler
      • Lebanon, Pennsylvania, Verenigde Staten, 17042
        • Werving
        • Sechler Family Cancer Center
        • Contact:
        • Hoofdonderzoeker:
          • Marianne Spengler
      • York, Pennsylvania, Verenigde Staten, 17403
        • Werving
        • WellSpan Health-York Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 877-441-7957
        • Hoofdonderzoeker:
          • Marianne Spengler
      • York, Pennsylvania, Verenigde Staten, 17403
        • Geschorst
        • Cancer Care Associates of York
    • Rhode Island
      • Westerly, Rhode Island, Verenigde Staten, 02891
        • Werving
        • Smilow Cancer Hospital Care Center - Westerly
        • Contact:
        • Hoofdonderzoeker:
          • Matthew Austin
    • South Carolina
      • Charleston, South Carolina, Verenigde Staten, 29425
        • Geschorst
        • Medical University of South Carolina
      • Rock Hill, South Carolina, Verenigde Staten, 29732
        • Werving
        • Levine Cancer Institute-Rock Hill
        • Hoofdonderzoeker:
          • Earle F. Burgess
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-9376
    • South Dakota
      • Rapid City, South Dakota, Verenigde Staten, 57701
        • Werving
        • Rapid City Regional Hospital
        • Hoofdonderzoeker:
          • Abdel-Ghani Azzouqa
        • Contact:
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Werving
        • Vanderbilt University/Ingram Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-811-8480
        • Hoofdonderzoeker:
          • Robert A. Ramirez
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
        • Werving
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Contact:
        • Hoofdonderzoeker:
          • Namrata I. Peswani
      • Dallas, Texas, Verenigde Staten, 75235
        • Werving
        • Parkland Memorial Hospital
        • Contact:
        • Hoofdonderzoeker:
          • Namrata I. Peswani
      • Dallas, Texas, Verenigde Staten, 75237
        • Werving
        • UT Southwestern Simmons Cancer Center - RedBird
        • Hoofdonderzoeker:
          • Namrata I. Peswani
        • Contact:
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Werving
        • UT Southwestern/Simmons Cancer Center-Fort Worth
        • Contact:
        • Hoofdonderzoeker:
          • Namrata I. Peswani
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
        • Hoofdonderzoeker:
          • Tannaz Armaghany
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 713-798-1354
          • E-mail: burton@bcm.edu
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • Ben Taub General Hospital
        • Hoofdonderzoeker:
          • Tannaz Armaghany
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 713-873-2000
      • Richardson, Texas, Verenigde Staten, 75080
        • Werving
        • UT Southwestern Clinical Center at Richardson/Plano
        • Contact:
        • Hoofdonderzoeker:
          • Namrata I. Peswani
    • Utah
      • Salt Lake City, Utah, Verenigde Staten, 84112
        • Werving
        • Huntsman Cancer Institute/University of Utah
        • Contact:
        • Hoofdonderzoeker:
          • Heloisa P. Soares
    • Vermont
      • Saint Johnsbury, Vermont, Verenigde Staten, 05819
        • Werving
        • Dartmouth Cancer Center - North
        • Contact:
        • Hoofdonderzoeker:
          • Kathryn C. Hourdequin
    • Washington
      • Seattle, Washington, Verenigde Staten, 98195
        • Werving
        • University of Washington Medical Center - Montlake
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-8824
        • Hoofdonderzoeker:
          • David B. Zhen
      • Seattle, Washington, Verenigde Staten, 98109
        • Werving
        • Fred Hutchinson Cancer Center
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 800-804-8824
        • Hoofdonderzoeker:
          • David B. Zhen
    • West Virginia
      • Bridgeport, West Virginia, Verenigde Staten, 26330
        • Werving
        • United Hospital Center
        • Contact:
        • Hoofdonderzoeker:
          • Nour Daboul
      • Morgantown, West Virginia, Verenigde Staten, 26506
        • Werving
        • West Virginia University Healthcare
        • Contact:
        • Hoofdonderzoeker:
          • Nour Daboul
    • Wisconsin
      • Eau Claire, Wisconsin, Verenigde Staten, 54701
      • La Crosse, Wisconsin, Verenigde Staten, 54601
        • Werving
        • Gundersen Lutheran Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • David E. Marinier
      • Marshfield, Wisconsin, Verenigde Staten, 54449
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Werving
        • Medical College of Wisconsin
        • Contact:
          • Site Public Contact
          • Telefoonnummer: 414-805-3666
        • Hoofdonderzoeker:
          • Alexandria T. Phan
      • Minocqua, Wisconsin, Verenigde Staten, 54548
      • Rice Lake, Wisconsin, Verenigde Staten, 54868
      • Stevens Point, Wisconsin, Verenigde Staten, 54482
      • Weston, Wisconsin, Verenigde Staten, 54476

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC)

  • Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator

  • Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form

  • Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply:

    • Participants who have received treatment for brain metastases must have:

      • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
      • Discontinued all corticosteroids at least 14 days prior to registration
    • Participants with treatment-naive brain lesions must have:

      • No lesion measuring > 2.0 cm in size in any axis
      • MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration
      • No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
      • No need for > 2 mg of dexamethasone (or equivalent of > 10 mg prednisone) per day at time of registration
  • Participants must not have symptomatic central nervous system (CNS) metastases

  • Participants must not have known or suspected leptomeningeal disease

  • Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed >= 6 months prior to registration

  • Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study

  • Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed >= 24 weeks prior to registration and participants have recovered from all prior toxicities to =< grade 1.

  • Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration

  • Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 [IL-2] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration

  • Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide

  • Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted.

  • Participants must be >= 18 years of age

  • Participants must have a Zubrod performance status of =< 2 within 28 days prior to registration

  • Participants must have a complete medical history and physical exam within 28 days prior to registration

  • Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Hemoglobin >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Platelet count >= 100 x 10^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Serum total bilirubin =< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) > 50 mL/min OR 2) Calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)

  • Participants must not have uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned

  • Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of > 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration

  • Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study

    • Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study

    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

      • Rash must cover < 10% of body surface area
      • Disease is well controlled at baseline and requires only low-potency topical corticosteroids
      • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  • Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted

  • Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina

  • Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery

  • Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia

  • Participants must not have known active tuberculosis

  • Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated

  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated

  • Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration

  • Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant

  • Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist [registered trademark]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab

  • Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

  • Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System

  • Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Arm I (atezolizumab, platinum drug, etoposide)

During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

Given IV

Andere namen:
  • Blastocarb
  • Carboplat
  • Carboplatine Hexal
  • Carboplatino
  • Carboplatina
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatine
  • Paraplatina AQ
  • Platinawas
  • Ribocarbo
  • JM8

Given IV

Andere namen:
  • CDDP
  • Cis-diamminedichloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatine
  • Platina
  • Abiplatine
  • Blastolem
  • Briplatine
  • Cis-diammine-dichloorplatina
  • Cis-diamminedichloor Platina (II)
  • Cis-diamminedichloorplatina
  • Cis-dichlooramine platina (II)
  • Cis-platina Diamine Dichloride
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diaminedichloride
  • Cisplatine
  • Cisplatyl
  • Citoplatina
  • Citosine
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatine
  • Chloride van Peyrone
  • Zout van Peyrone
  • Plaats
  • Kunststof
  • Platamine
  • Platiblastine
  • Platiblastine-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxaan
  • Platina diamminodichloride
  • Platiraans
  • Platistine
  • Platosine

Undergo blood sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Given IV

Andere namen:
  • Demethyl Epipodofyllotoxine Ethylidine Glucoside
  • EPEG
  • Laatste
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Given IV

Andere namen:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RG 7446
  • RO-5541267
Experimenteel: Arm II (atezolizumab, platinum drug, etoposide, observation)

During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. (CLOSED TO ACCRUAL 7/9/26)

Given IV

Andere namen:
  • Blastocarb
  • Carboplat
  • Carboplatine Hexal
  • Carboplatino
  • Carboplatina
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatine
  • Paraplatina AQ
  • Platinawas
  • Ribocarbo
  • JM8

Given IV

Andere namen:
  • CDDP
  • Cis-diamminedichloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatine
  • Platina
  • Abiplatine
  • Blastolem
  • Briplatine
  • Cis-diammine-dichloorplatina
  • Cis-diamminedichloor Platina (II)
  • Cis-diamminedichloorplatina
  • Cis-dichlooramine platina (II)
  • Cis-platina Diamine Dichloride
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diaminedichloride
  • Cisplatine
  • Cisplatyl
  • Citoplatina
  • Citosine
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatine
  • Chloride van Peyrone
  • Zout van Peyrone
  • Plaats
  • Kunststof
  • Platamine
  • Platiblastine
  • Platiblastine-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxaan
  • Platina diamminodichloride
  • Platiraans
  • Platistine
  • Platosine

Undergo blood sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Given IV

Andere namen:
  • Demethyl Epipodofyllotoxine Ethylidine Glucoside
  • EPEG
  • Laatste
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Undergo observation

Andere namen:
  • Observatie
  • Actief toezicht
  • uitgestelde therapie
  • afwachtend beheer
  • Waakzaam wachten

Given IV

Andere namen:
  • Tecentriq
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 3280A
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RG 7446
  • RO-5541267
Actieve vergelijker: Arm III (platinum drug, etoposide, observation)

During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study.

Given IV

Andere namen:
  • Blastocarb
  • Carboplat
  • Carboplatine Hexal
  • Carboplatino
  • Carboplatina
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatine
  • Paraplatina AQ
  • Platinawas
  • Ribocarbo
  • JM8

Given IV

Andere namen:
  • CDDP
  • Cis-diamminedichloridoplatina
  • Cismaplat
  • Cisplatina
  • Neoplatine
  • Platina
  • Abiplatine
  • Blastolem
  • Briplatine
  • Cis-diammine-dichloorplatina
  • Cis-diamminedichloor Platina (II)
  • Cis-diamminedichloorplatina
  • Cis-dichlooramine platina (II)
  • Cis-platina Diamine Dichloride
  • Cis-platina
  • Cis-platina II
  • Cis-platina II diaminedichloride
  • Cisplatine
  • Cisplatyl
  • Citoplatina
  • Citosine
  • Cysplatina
  • DDP
  • Lederplatina
  • Metaplatine
  • Chloride van Peyrone
  • Zout van Peyrone
  • Plaats
  • Kunststof
  • Platamine
  • Platiblastine
  • Platiblastine-S
  • Platinex
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxaan
  • Platina diamminodichloride
  • Platiraans
  • Platistine
  • Platosine

Undergo blood sample collection

Andere namen:
  • Biologische monsterverzameling
  • Biospecimen verzameld
  • Specimenverzameling
  • Monsterverzameling

Undergo MRI

Andere namen:
  • MRI
  • Magnetische resonantie
  • Magnetic Resonance Imaging-scan
  • Medische beeldvorming, magnetische resonantie / nucleaire magnetische resonantie
  • DHR
  • MR-beeldvorming
  • MRI scan
  • NMR-beeldvorming
  • NMRI
  • Nucleaire magnetische resonantie beeldvorming
  • Magnetische resonantiebeeldvorming (MRI)
  • sMRI
  • Magnetische resonantiebeeldvorming (procedure)
  • MRI's
  • Structurele MRI

Given IV

Andere namen:
  • Demethyl Epipodofyllotoxine Ethylidine Glucoside
  • EPEG
  • Laatste
  • Toposar
  • Vepesid
  • VP 16
  • VP 16-213
  • VP-16
  • VP-16-213
  • VP16
  • VP 16213
  • VP-16213
  • VP16213

Undergo CT scan

Andere namen:
  • CT
  • KAT
  • CT-scan
  • Axiale computertomografie
  • Computergestuurde axiale tomografie
  • Computergestuurde tomografie
  • tomografie
  • Geautomatiseerde axiale tomografie (procedure)
  • Computertomografie (CT)-scan
  • Diagnostische kattencan
  • Diagnostisch CAT -scanservice type

Undergo observation

Andere namen:
  • Observatie
  • Actief toezicht
  • uitgestelde therapie
  • afwachtend beheer
  • Waakzaam wachten

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Overall survival
Tijdsspanne: From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years

Log-rank tests stratified by the randomization stratification factors will be used for null hypothesis (efficacy) tests. Cox regression models stratified by the randomization stratification factors will be used for alternative hypothesis (futility) tests.

From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Progression-free survival
Tijdsspanne: From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years

Will be estimated using the Kaplan-Meier method and compared using log-rank tests.

From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
Duration of response
Tijdsspanne: Time from date of initial response to date of progression or death, assessed up to 5 years

Will be estimated non-parametrically using cumulative incidence curves.

Time from date of initial response to date of progression or death, assessed up to 5 years
Objective response rate (confirmed complete response [CR] or partial response [PR])
Tijdsspanne: Up to 5 years from study enrollment

Will be tabulated and compared between arms using Fisher's exact test.

Up to 5 years from study enrollment
Clinical benefit rate (confirmed CR or PR of any amount of time or stable disease for 6 months or longer)
Tijdsspanne: Up to 5 years from study enrollment

Will be tabulated and compared between arms using Fisher's exact test.

Up to 5 years from study enrollment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: David B Zhen, SWOG Cancer Research Network

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

28 juni 2022

Primaire voltooiing (Geschat)

1 oktober 2028

Studie voltooiing (Geschat)

1 oktober 2028

Studieregistratiedata

Eerst ingediend

25 september 2021

Eerst ingediend dat voldeed aan de QC-criteria

25 september 2021

Eerst geplaatst (Werkelijk)

28 september 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

17 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren